Search

Displaying results 6441 - 6450 of 10000 in total
  1. Drug

    Pardoprunox

    go.drugbank.com/drugs/DB12061
    Investigational

    Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease.

  2. Drug

    Toyocamycin

    go.drugbank.com/drugs/DB13916
    Experimental

    It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.

  3. Drug

    Dichlorobenzene

    go.drugbank.com/drugs/DB14046
    ApprovedWithdrawn

    Dichlorobenzene refers to any of, or a mixture of, three isomers consisting of benzene in which two of the hydrogen atoms are replaced by chlorine atoms: ortho-, meta-, and paradichlorobenzene.

  4. Drug

    (S)-Warfarin

    go.drugbank.com/drugs/DB14055
    Investigational

    S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.[A7166]

  5. Drug

    Cemivameran

    go.drugbank.com/drugs/DB19415
    Approved

    It is the active ingredient in the 2024-2025 formulation of Pfizer-BioNTech's Comirnaty vaccine.[L36030]

  6. Drug

    Velaglucerase alfa

    go.drugbank.com/drugs/DB06720
    Approved

    Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.

  7. Drug

    Cefmetazole

    go.drugbank.com/drugs/DB00274
    Approved

    It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.

    Synonyms: (6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  8. Drug

    MF-300

    go.drugbank.com/drugs/DB32060
    Investigational

    MF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase.

  9. Drug

    T487

    go.drugbank.com/drugs/DB05474
    Experimental

    The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.

  10. Drug

    AVR-RD-04

    go.drugbank.com/drugs/DB18644
    Experimental

    AVR-RD-04 is an investigational gene therapy for cystinosis. … It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin.

    Synonyms: autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin